Foretinib (GSK1363089)

目录号:S1111 别名: EXEL-2880,XL-880

Foretinib (GSK1363089) Chemical Structure

Molecular Weight(MW): 632.65

Foretinib (GSK1363089)是一种ATP竞争性的HGFR和VEGFR抑制剂,对MetKDR作用最强,在无细胞试验中IC50分别为0.4 nM和0.9 nM。对Ron, Flt-1/3/4, Kit, PDGFRα/β和Tie-2作用效果稍弱,对FGFR1和EGFR几乎没有抑制活性。Phase 2。

规格 价格 库存 购买数量  
In DMSO RMB 2340.27 现货
RMB 1374.78 现货
RMB 7124.95 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献35篇:

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述 Foretinib (GSK1363089)是一种ATP竞争性的HGFR和VEGFR抑制剂,对MetKDR作用最强,在无细胞试验中IC50分别为0.4 nM和0.9 nM。对Ron, Flt-1/3/4, Kit, PDGFRα/β和Tie-2作用效果稍弱,对FGFR1和EGFR几乎没有抑制活性。Phase 2。
靶点
Met [1]
(Cell-free assay)
KDR [1]
(Cell-free assay)
Tie-2 [1]
(Cell-free assay)
VEGFR3/FLT4 [1]
(Cell-free assay)
RON [1]
(Cell-free assay)
0.4 nM 0.86 nM 1.1 nM 2.8 nM 3 nM
体外研究

XL880抑制HGF受体家族酪氨酸激酶,对Met和Ron 的IC50 值分别为0.4 nM和3 nM。XL880也会抑制KDR,Flt-1,和Flt-4,IC50值分别为0.9 nM,6.8 nM和2.8 nM。XL880抑制B16F10,A549 和HT29细胞集落生长,IC50分别为40 nM,29 nM和165 nM。[1]一项最近的研究表明,XL880差异性影响胃癌细胞系MKN-45和KATO-III的细胞生长。XL880抑制MKN-45细胞中MET和下游信号分子的磷酸化,而在KATO-III细胞中靶向作用于GFGR2。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Daoy  MkHPSpVv[3Srb36gRZN{[Xl? NVywNGhnOC53L{GvNk42KM7:TR?= MkLDNlQhcA>? MV3EUXNQ NXvE[llncW6qaXLpeJMhfGinIFjHSk1qdmS3Y3XkJINOTVRicHH0bJdigSCjY4TpeoF1cW:w MlroNlU{QTF{NEG=
ONS76 MXXGeY5kfGmxbjDBd5NigQ>? NH;jTYQxNjVxMT:yMlUh|ryP NIDFd2wzPCCq NITGfnRFVVOR MVfpcohq[mm2czD0bIUhUEeILXnu[JVk\WRiY13FWEBx[XSqd3H5JIFkfGm4YYTpc44> Ml\0NlU{QTF{NEG=
Daoy  MXPGeY5kfGmxbjDBd5NigQ>? NFTm[pExNjVxMT:yMlUh|ryP M1XvfFI1KGh? M2npdGROW09? MWPpcohq[mm2czDIS2YudWWmaXH0[YQhdWmpcnH0bY9vKGGwZDDpcpZie2mxbh?= NGHX[nEzPTN7MUK0NS=>
ONS76 MXvGeY5kfGmxbjDBd5NigQ>? MlXYNE42NzFxMj61JO69VQ>? M4LjSlI1KGh? NFHo[W9FVVOR MULpcohq[mm2czDIS2YudWWmaXH0[YQhdWmpcnH0bY9vKGGwZDDpcpZie2mxbh?= MV:yOVM6OTJ2MR?=
Daoy  NX7tNldxSXCxcITvd4l{KEG|c3H5 M2DCOVEh|ryP MWiyOEBp MXrEUXNQ NEjsPYlqdmS3Y3XzJIFxd3C2b4Ppdy=> Mk\ENlU{QTF{NEG=
Daoy  MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHThdVcxNjVxMT:yMlUh|ryP M4LETVI1NTl4IHi= MkDySG1UVw>? MkHJbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mm\HNlU{QTF{NEG=
U251 MXvGeY5kfGmxbjDBd5NigQ>? M{HvSlExOC9|MECvPVAxKG6P NHT5c3kyKGh? NGjMV3VFVVOR NULtbWF{cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDN[ZJVU8Li M33FRVI1PjV6M{K2
A172 NH7XU4dHfW6ldHnvckBCe3OjeR?= M2H2UFExOC9|MECvPVAxKG6P NYDaU4toOSCq NXfOXoFnTE2VTx?= MYDpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKE2ncmTLxsA> M2LJRVI1PjV6M{K2
SF188 M1;0c2Z2dmO2aX;uJGF{e2G7 MYCxNFAwOzByL{mwNEBvVQ>? M3jYOlEhcA>? NIjK[WFFVVOR NVrFSpF7cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDN[ZJVU8Li NYPMZZM5OjR4NUizNlY>
U251 NH:xbGdHfW6ldHnvckBCe3OjeR?= NEn3NYQyODBxM{CwM|kxOCCwTR?= M2WyUVEhcA>? MnPaSG1UVw>? NGLlVXVqdmirYnn0d{B1cGViYXP0bZZqfHlib3[gRZhtNCCWeYLvNy=> NVywZnpNOjR4NUizNlY>
A172 M3jlO2Z2dmO2aX;uJGF{e2G7 NWHpWIJsOTByL{OwNE86ODBibl2= M{TsbVEhcA>? M1XjfmROW09? MXHpcohq[mm2czD0bIUh[WO2aY\peJkhd2ZiQYjsMEBVgXKxMx?= MUiyOFY2QDN{Nh?=
SF188 MlWxSpVv[3Srb36gRZN{[Xl? NVztdGFrOTByL{OwNE86ODBibl2= M1T3Z|EhcA>? NWXEe3N1TE2VTx?= MnvGbY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIFH4cEwhXHm{b{O= MlHvNlQ3PTh|Mk[=
U251 Ml;jSpVv[3Srb36gRZN{[Xl? MXGxNFAwOzByL{mwNEBvVQ>? M1TOZVEhcA>? M{\aT2ROW09? M2XNWoRm[3KnYYPld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGgZ49v[2WwdILheIlwdiCmZYDlcoRmdnRibXHucoVz MoX3NlQ3PTh|Mk[=
A172 NYPzSWRpTnWwY4Tpc44hSXO|YYm= NEP1NXUyODBxM{CwM|kxOCCwTR?= NGPZ[4MyKGh? NYryTJRCTE2VTx?= M4\DNIRm[3KnYYPld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGgZ49v[2WwdILheIlwdiCmZYDlcoRmdnRibXHucoVz MV[yOFY2QDN{Nh?=
SF188 MkLPSpVv[3Srb36gRZN{[Xl? NI\yeHEyODBxM{CwM|kxOCCwTR?= NYXwW|lZOSCq NHLJdlVFVVOR MUTk[YNz\WG|ZYOgRYt1KHCqb4PwbI9zgWyjdHnvckBqdiCjIHPvcoNmdnS{YYTpc44h\GWyZX7k[Y51KG2jbn7ldi=> MViyOFY2QDN{Nh?=
U251 MnHCSpVv[3Srb36gRZN{[Xl? NIWyUYYyODBxM{CwM|kxOCCwTR?= NWnKO25qOjhiaB?= NGXGUo5FVVOR NIHCdG5qdmS3Y3XzJHBCWlBiY3zlZZZi\2V? MkXUNlQ3PTh|Mk[=
SF188 MUjGeY5kfGmxbjDBd5NigQ>? NWDTTFRtOTByL{OwNE86ODBibl2= MVyyPEBp MVrEUXNQ M12ycolv\HWlZYOgVGFTWCClbHXheoFo\Q>? MVGyOFY2QDN{Nh?=
SF188 NGPSWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\vN4syODBxM{CwM|kxOCCwTR?= M1LaNlQ5KGh? MmS4SG1UVw>? MoLTdoVlfWOnczDj[YxtKHO3co\peoFtKGG2IEmwNEBvVSC|aXfubYZq[2GwdHz5 M3LGSFI1PjV6M{K2
U251 M2XmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn3NVAxNzNyMD:5NFAhdk1? NX\JO5pwPDhiaB?= MUDEUXNQ NIXie4lz\WS3Y3XzJINmdGxic4Xyeol3[WxiYYSgPVAxKG6PIIPp[45q\mmlYX70cJk> Ml7HNlQ3PTh|Mk[=
A172 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPYcFVLOTByL{OwNE86ODBibl2= M3zCWVQ5KGh? Mon2SG1UVw>? NUD1RZh2emWmdXPld{Bk\WyuIIP1dpZqfmGuIHH0JFkxOCCwTTDzbYdvcW[rY3HueIx6 NUTydXNUOjR4NUizNlY>
SF188 NFXYbolHfW6ldHnvckBCe3OjeR?= NIPwVJUyODBxM{CwM|kxOCCwTR?= MYCyOEBp MmD2SG1UVw>? M1LPeYFjem:pYYTld{BucWe{YYTpc44h[W6mIHnueoF{cW:wIH;mJIdtcW:vYTDj[YxteyCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MYGyOFY2QDN{Nh?=
U251 NUCwepN3TnWwY4Tpc44hSXO|YYm= MlP6NVAxNzNyMD:5NFAhdk1? NHHzNGczPCCq NVfRTVdSTE2VTx?= M3q5[YFjem:pYYTld{BucWe{YYTpc44h[W6mIHnueoF{cW:wIH;mJIdtcW:vYTDj[YxteyCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NUjtRoZ7OjR4NUizNlY>
A172 MXHGeY5kfGmxbjDBd5NigQ>? M2XVXVExOC9|MECvPVAxKG6P NEHoZZEzPCCq MXrEUXNQ MY\hZpJw\2G2ZYOgcYloemG2aX;uJIFv\CCrbo\hd4lwdiCxZjDncIlwdWFiY3XscJMhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NWDHUFk4OjR4NUizNlY>
Ba/F3 M3LQ[mNmdGxiVnnhZoltcXS7IFHzd4F6 NFqwbVExNjByMEGtNVAh|ryP M2q1VlczKGh? Mn;QbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M{nz[lI1OjF6NUi5
HCC78 NHTFW2JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVi2S48xOC5yMT2xNEDPxE1? NGHQPFU4OiCq M2\He4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MnfGNlQzOTh3OEm=
SK-HEP1 MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3zMTlAvOjVvMT61JO69VQ>? MW[yOOKhcA>? MkPLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NYHLOYl6OjJzOEexO|E>
SK-HEP2 NHnlSWhHfW6ldHnvckBCe3OjeR?= MmizNUDPxE1? M{PoelI1KGh? MWnicI9kc3NiSFfGMYlv\HWlZXSgZ4VtdCCvb4TpcIl1gQ>? M1zBOVIzOTh5MUex
SK-HEP2 MXzGeY5kfGmxbjDBd5NigQ>? M4fvcFEh|ryP NYfCTXBQOjRiaB?= MnLUZ4F2e2W|IFeyM20heGijc3WgZZJz\XO2IIfpeIghemWmdXP0bY9vKGmwIITo[UBIOC:JMdMgZY5lKFNicHjhd4V{ MUOyNlE5PzF5MR?=
MKN-45  MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS5NE4xOS1zMDFOwG0> NFTSWFY2KGR? MmXSTWM2OD16IH7N NXvFd4x5OjF4NUW5NVg>
KATO-III MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOwMlAyNTFyIN88US=> MkHhOUBl NV7HNGl6UUN3ME2zNEBvVQ>? Mo\CNlE3PTV7MUi=
MKN-45  NUPhTpVoTnWwY4Tpc44hSXO|YYm= M3[0NlEh|ryP MXqyOEBp MX7pcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gUWVVNCCDa4SsJIFv\CCHUluxM|IhcW5iTVvOMVQ2 NIPS[oUzOTZ3NUmxPC=>
KATO-III MUHGeY5kfGmxbjDBd5NigQ>? NWnKbnBYOSEQvF2= NHrJNXAzPCCq Mk\ubY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJG1GXCxiQXv0MEBidmRiRWLLNU8zKGmwIF3LUk01PQ>? NWL6clduOjF4NUW5NVg>
H1648 MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\McGlEPTB;MT6yPEDDuTBwMUKg{txO MX6yNVI2OjJ6NB?=
H1573 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqxTWM2OD1zLk[yJOKyKDBwMEWg{txO NYXHR2l3OjF{NUKyPFQ>
H596 M4LSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwMkGgxtEhOC5zNzFOwG0> M{njRVIyOjV{Mki0
HOP92 NUPLeVlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDyZmdKSzVyPUCuPFEhyrFiMD6yPUDPxE1? M2D0W|IyOjV{Mki0
H69 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonWTWM2OD1zLkG4JOKyKDBwMEig{txO NWO3WYR{OjF{NUKyPFQ>
H1975 M2Li[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwM{mgxtEhOC5|MzFOwG0> M1jCNVIyOjV{Mki0
SCC15 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITOWXBKSzVyPUCuOlMhyrFiMD6wOEDPxE1? MnzmNlEzPTJ{OES=
HN5 NInub45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwNkWgxtEhOC5{NjFOwG0> M2rs[lIyOjV{Mki0

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Met / Met / p-Akt / Akt ; 

PubMed: 29854314     


After serum starvation, the cells were treated with vehicle or foretinib for 24 hours. The cell lysates were analyzed by Western blotting using antibodies against p-Met, Met, p-Akt and Akt. Representative examples of bands from Western blots

p-MDM2 / p53 / PUMA ; 

PubMed: 29854314     


After serum starvation, the cells were treated with vehicle or foretinib for 24 hours. The cell lysates were analyzed by Western blotting using antibodies against p-MDM2, p53, PUMA and ACTB. 

pROS1 / tROS1 / pSHP2 / pERK / ERK ; 

PubMed: 24218589     


Immunoblot analysis of FIG-ROS fusion protein phosphorylation and downstream effector modulation after varying doses of crizotinib and foretinib. Cropped images representative of three independent experiments are shown.

29854314 24218589
Growth inhibition assay
Cell viability ; 

PubMed: 29854314     


EC cells were treated with various concentrations of foretinib for 48 hours and then their proliferation was measured by an MTS assay. 

29854314
体内研究 XL880(100 mg/kg,单一剂量,口服强喂)很大程度上抑制B16F10肿瘤Met的磷酸化和配体(比如,HGFor VEGF)诱导的肝脏中Met和肺中Flk-1/KDR受体磷酸化,两者都能持续24小时。XL880 (30-100 mg/kg,每天一次,口服强喂)处理导致肿瘤负荷减少。30和100 mg/kg XL880处理后,肺表面肿瘤负荷分别减少50%和58%。XL880处理负荷B16F10实体瘤的小鼠也会导致剂量依赖性肿瘤生长抑制,30和100 mg/kg分别导致64%和87%的抑制。对于这两项研究,XL880给药具有良好的耐受性,并且没有显著的体重损失。[1] XL880通过Met可以进一步以HGF的反常信号为作用靶点,同时靶向作用于几个参与肿瘤血管生成的受体酪氨酸激酶。XL880给药2到4小时后,引起人异种移植物中肿瘤出血坏死,96小时(给药5天后)观察到最大肿瘤坏死,导致完全的肿瘤消退。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

激酶抑制试验:

激酶抑制使用三种测定形式中的一种进行研究:[33P]磷酰基转移法,荧光素酶耦合的化学发光法,或AlphaScreen酪氨酸激酶技术。IC50s使用XLFit通过非线性回归分析计算。33P-磷酰基转移激酶实验反应在384孔白色,透明底,高结合力微量滴定板(Greiner,Monroe,NC)中进行。板用50 μL体积的涂层缓冲液中的2 μg/well蛋白质或多肽底物涂覆,涂层缓冲液包含40 μg/mL底物(poly(Glu, Tyr) 4:1,22.5 mM Na2CO3,27.5 mM NaHCO3,50 mM NaCl 和3 mM NaN 3。涂层的板用50 μL实验缓冲液洗涤一次,然后在室温下(RT)过夜培养。测试化合物和酶与33P-γ-ATP (3.3 μCi/nmol)结合,总体积为20 μL。反应混合物在室温下培养2小时,然后通过抽吸终止。随后微量滴定板用0.05% Tween-PBS缓冲液(PBST)清洗6次。加入闪烁液(50 μL/well),整合的33P使用MicroBeta闪烁计数器通过液体闪烁光谱法测量。荧光素酶耦合的化学发光反应在384孔白色,含培养基的微量滴定板(Greiner)中进行。第一步,酶和化合物结合,并培养60分钟;加入终体积为20 μL的ATP与多肽底物(poly(Glu, Tyr) 4:1)起始反应,在室温下培养2-4小时。接下来进行激酶反应,加入20 μL等分激酶Glo (Promega,Madison,WI),荧光信号使用Victor酶标仪测量。总ATP消耗限制在50%。AlphaScreenTM酪氨酸激酶测定使用链霉亲和素涂覆的供体珠和PY100抗磷酸酪氨酸抗体涂覆的受体珠进行。生物素化的聚(Glu,Tyr) 4:1用作底物。通过加入供体/受体珠,随后形成供体/受体珠复合物产生荧光测量底物磷酸化。激酶与测试化合物结合,并预培养60分钟,随后加入总体积为20 μL 的ATP,和生物素化的聚(Glu, Tyr)在384孔白色,含培养基的微量滴定板(Greiner)中。反应混合物在室温下培养1小时。然后加入包含75 mM Hepes,pH 7.4,300 mM NaCl,120 mM EDTA,0.3% BSA和0.03% Tween-20的10 μL 15-30 μg/mL AlphaScreen 珠悬浮液淬灭反应。室温下培养2-16小时后,板使用AlphaQuest阅读器读取数据。
细胞实验:

[1]

- 合并
  • Cell lines: B16F10,A549,和 HT29 细胞
  • Concentrations: 40 nM
  • Incubation Time: 12 到 14 天
  • Method: B16F10,A549,和HT29细胞(1.2×103/孔)与软琼脂混合,并接种于包含超过琼脂层的10% FBS 和EXEL-2880的96孔板。对于含氧量正常的条件,板在21%氧气,5% CO2,和74% 氮气中培养(37 ℃)12到14天,而低氧条件下的培养(37℃)在1% 氧气,5% CO2,和94%氮气的低氧培养室中进行。每个条件下的集落数量在加入50% Alamar Blue,进行荧光检测后评估。
    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: B16F10 肿瘤细胞(2×10 5)通过胃部静脉注射植入5到8周大的无胸腺裸鼠(NCr 或 BALB/c)
  • Formulation: 0.9% 生理盐水
  • Dosages: 100 mg/kg
  • Administration: 口服强饲
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (158.06 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 632.65
化学式

C34H34F2N4O6

CAS号 849217-64-7
储存条件 粉状
溶于溶剂
别名 EXEL-2880,XL-880

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00920192 Completed Drug: Foretinib Carcinoma Hepatocellular GlaxoSmithKline August 12 2009 Phase 1
NCT00742261 Completed Drug: GSK1363089 Solid Tumours GlaxoSmithKline August 11 2008 Phase 1
NCT00725764 Completed Drug: GSK1363089 (foretinib) Neoplasms Head and Neck GlaxoSmithKline August 27 2007 Phase 2
NCT00725712 Completed Drug: GSK1363089 (formerly XL880) Neoplasms Gastrointestinal Tract GlaxoSmithKline March 31 2007 Phase 2
NCT00743067 Completed Drug: GSK1363089 (formerly XL880) Solid Tumours GlaxoSmithKline August 9 2006 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品

Tags: 购买Foretinib (GSK1363089) | Foretinib (GSK1363089)供应商 | 采购Foretinib (GSK1363089) | Foretinib (GSK1363089)价格 | Foretinib (GSK1363089)生产 | 订购Foretinib (GSK1363089) | Foretinib (GSK1363089)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID